Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina Inc (NQ: ILMN )

220.00 +3.05 (+1.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Illumina Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Following Rough Year, Is Burning Rock Set To Turn The Corner?
Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due to latest Covid-related travel restrictions in China Cancer testing specialist’s... 
Via Benzinga
Europe To Layout Objections to Illumina-Grail Deal: Bloomberg
Illumina Inc (NASDAQ: ILMN) says the European Union will issue a list of objections tomorrow over the Company's $8B takeover of GRAIL, Bloomberg reports. Related... 
Via Benzinga
Illumina Clocks 40% Growth In Q3; Earnings Beat Expectations
Illumina Inc (NASDAQ: ILMN) reported Q3 revenues of $1.11 billion, +40% Y/Y, beating the consensus of $1.04 billion. Consolidated Product revenues were $978 million,... 
Via Benzinga
Topics Earnings
Exposures Financial
Illumina, inc (ILMN) Q3 2021 Earnings Call Transcript
ILMN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
After Its Grail Buyout, Illumina Beats Third-Quarter Expectations
Illumina stock inched higher late Thursday after the company beat forecasts. 
Via Investor's Business Daily
Illumina slides after 'Confusing' close of Grail deal amid antitrust probe
Citi sees some risk that Illumina's tactic does not sit well with the regulatory bodies. 
Via Talk Markets
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
'Halftime Report' Final Trades From Oct. 25: Illumina, JPMorgan, And More
On CNBC’s "Halftime Report" f... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Bet On Biopharma: Data, Digitization, Discovery
The after-effects of pandemic-era policies will be with us for some time — with many supply chains still experiencing significant disruption. The worst of this “scarring” will heal. But the... 
Via Talk Markets
Illumina Insider Sold $1.2M In Company Stock
Alexander Aravanis, SVP And Chief Technology Officer at Illumina (NASDAQ:ILMN), made a large insider sell on October 12, according to a new SEC filing. What Happened: A Form 4... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Shares of Ilumina Slumped 11.3% in September
The company's merger with GRAIL concerned investors. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Some trends will persist for decades. 
Via The Motley Fool
UK's NHS Launches World's Largest Trial Of Blood Test For 50 Types
Britain's National Health Service (NHS) will begin the world's largest trial of Grail Inc's flagship Galleri blood test that can be used to detect... 
Via Benzinga
Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay
Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge... 
Via Benzinga
Why Illumina Wants Grail Back So Badly
The gene-sequencing giant sees a huge opportunity in diagnostics. 
Via The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
Workday And Lam Research Lead The QQQ
U.S. indices were trading higher Friday as investors eye Fed Chairman Powell's speech at the Jackson Hole Symposium and gauge Fed tapering policy. The Invesco QQQ Trust... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Looking into Illumina's Return on Capital Employed
Pulled from Benzinga Pro data Illumina (NASDAQ:ILMN) showed a loss in earnings since Q1, totaling $187.00 million. Sales, on the other hand, increased by 3.02% to $1.13 billion... 
Via Benzinga
Friday Fears and Other Stock News Updates
Toyota has cut its output 40% over fear of the Delta variant of Covid, plus shortages of electronics. This is terrifying markets outside the USA. And other global stock news updates. 
Via Talk Markets
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
Microsoft And Cisco Gain As The QQQ Bounces Back Thursday
U.S. indices bounced back Thursday after falling Wednesday amid macro uncertainty due to COVID-19 delta variant concerns. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained... 
Via Benzinga
Exposures COVID-19
Why Illumina Stock Just Dropped 10%
The genetic-testing company just blatantly defied its regulators. 
Via The Motley Fool
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial... 
Via Benzinga
Illumina Stock Nosedives After DNA Giant Makes A 'Maverick Move' In Its Grail Takeover
Illumina stock tumbled Thursday after the company finished its $8 billion acquisition of Grail despite an ongoing investigation in Europe. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: 
Via Benzinga
Illumina Completes Grail Buyout Despite Uncertainty In Regulatory Process
In defiance of FTC and EU scrutiny, Illumina Inc (NASDAQ: ILMN) went ahead to complete its $8 billion acquisition of Grail. The finalization of the buyout... 
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Providence Molecular Genomics Lab Utilizes Illumina Technology to Offer Genomics for All
Providence Molecular Genomics Lab Utilizes Illumina Technology to Offer Genomics for All 
Via News Direct
Topics Product Recall
Exposures Legal Product Safety
Illumina Stock Earns Membership In Elite Club
Illumina saw its IBD SmartSelect Composite Rating rise to 97 Tuesday, up from 93 the day before. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.